BMS BUYS RIGHTS TO PRM-151 AND PROMEDIOR

  • MPNRF | April 29, 2021

    August 31, 2015 

    Bristol-Myers Squibb has bought rights to a fibrosis drug and its privately held developer – Promedior.  The deal gives Bristol-Myers access to Promedior Inc’s lead experimental drug, PRM-151, which is being tested in myelofibrosis as well as diopathic pulmonary fibrosis.

    Promedior’s mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said on Monday.

    Click here for the full release.